Academic Journal
Q2Journal of Gastrointestinal Cancer
About Journal of Gastrointestinal Cancer
Journal of Gastrointestinal Cancer is a scholarly journal published by Springer. SCImago 2025 lists it in Q2, with an SJR of 0.584 and H-index of 56.
Coverage: 2007-2026. Research categories: Gastroenterology (Q2); Oncology (Q3).
Verified field sources
- Journal Impact Factor: 2.2 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Editor(s): Jordan Cloyd MD (Editor-in-Chief) — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Source-backed journal facts
Topics in published research
Gastric Cancer Management and Outcomes; Pancreatic and Hepatic Oncology Research; Hepatocellular Carcinoma Treatment and Prognosis; Cholangiocarcinoma and Gallbladder Cancer Studies; Gastrointestinal Tumor Research and Treatment; Colorectal Cancer Surgical Treatments.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,190.00 USD; 3,190.00 EUR; 2,790.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Fibrolamellar Carcinoma in the Molecular Era: From DNAJB1::PRKACA Biology to Precision Therapeutic Strategies
Tuba Baydaş, İlker Nihat Ökten
2026-10-03 · DOI: 10.1007/s12029-026-01610-yCorrespondence: Cachexia-Related Status in Advanced Gastric Cancer: Marker of Progression or Driver of Prognosis?
Yu Zhang
2026-10-01 · DOI: 10.1007/s12029-026-01612-wComparative Effectiveness and Safety of FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: A GRADE-assessed Systematic Review and Meta-analysis
Ahmed Raza, Maria Qadri, Faiza Fatima, Muhammad Saffi Ullah et al.
2026-09-30 · DOI: 10.1007/s12029-026-01595-8Correspondence: Radiation Boost to Lateral Pelvic Nodes in Rectal Cancer: Promising is not yet Proven
Yu Zhang
2026-09-29 · DOI: 10.1007/s12029-026-01607-7Perioperative Chemoimmunotherapy for Resectable Gastric and Gastroesophageal Junction Cancer: A Conceptual, Biomarker-Informed, and Regionally Adapted Framework
Tamotsu Sagawa, Hiroyuki Nagashima, Koshi Fujikawa
2026-09-29 · DOI: 10.1007/s12029-026-01602-yImpact of Socioeconomic Status on Early Gastric Cancer Outcomes and Treatment Disparity: a SEER analysis
Rinrada Worapongpaiboon, Sonmoon Mohapatra, Kasenee Tiankanon, Saowanee Ngamruengphong et al.
2026-09-28 · DOI: 10.1007/s12029-026-01604-wSecond-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis
Pouyan Shaker, Daniyaal Kamran, Lingling Du, Shubham Pant et al.
2026-09-28 · DOI: 10.1007/s12029-026-01601-zPerioperative Circulating Tumor DNA in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: Molecular Residual Disease, Recurrence Prediction, and a Trial-Ready Framework for Treatment Adaptation
Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa et al.
2026-09-25 · DOI: 10.1007/s12029-026-01598-5Global Perspectives on Radiotherapy Utilization for Pancreatic Ductal Adenocarcinoma
Bradley N. Reames, Eric D. Miller, Ziyi Zhou, Amol Narang et al.
2026-09-25 · DOI: 10.1007/s12029-026-01600-0Prognostic Value of the C-Reactive Protein–Albumin–Lymphocyte Index in Hepatobiliary and Pancreatic Cancers: A Systematic Review and Meta-Analysis
Mohammadsadra Shamohammadi, Ehsan Arianezhad, Danial Yarahmadi, Sana Ehsan Ullah et al.
2026-09-24 · DOI: 10.1007/s12029-026-01603-xEffectiveness and Safety of Colorectal Cancer Screening Via Fecal Occult Blood Testing: A Systematic Review and Meta-Analysis
Mayra Calil Jorge Frankenfeld, Giovanna Camarotto Patah, Luiza Teixeira Soares, Sarah Nascimento Silva et al.
2026-09-23 · DOI: 10.1007/s12029-026-01605-9Radiomics-Driven Imaging Biomarkers for Predicting Chemoradiotherapy Response in Locally Advanced Rectal Cancer
Jawad Ali Memon, Mohammad Sibtain Shah, Zubair Ali Memon, Uzma Malik et al.
2026-09-16 · DOI: 10.1007/s12029-026-01592-xLong-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score–Matched Retrospective Cohort Study Using the TriNetX Network
Muhammad Ali Ibrahim Kazi, Junaid Khan, Syed Musa Mufarrih, Maham Siddiqui et al.
2026-09-16 · DOI: 10.1007/s12029-026-01523-wPostoperative ctDNA-Guided Adjuvant Therapy in Resected Colorectal Cancer: A Systematic Review and Meta-analysis of Prognostic Validity Versus Treatment-Decision Utility
Zheng Han, Yan Zhang, Qingjie Tian, Hongcheng Zhu et al.
2026-09-16 · DOI: 10.1007/s12029-026-01578-9Induction FLOT Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in the Treatment of Lower Esophageal and Proximal Gastric Adenocarcinoma: A Phase II, Single-Arm Clinical Trial
Seyed Amir Aledavood, Zohreh Pishevar, Kazem Anvari, Ehsan Soltani et al.
2026-09-15 · DOI: 10.1007/s12029-026-01589-6Association of Cachexia-Related Status With Treatment Outcomes in Advanced Gastric Cancer Receiving First-Line Therapy With or Without Nivolumab
Hironori Fujii, Daichi Watanabe, Yunami Yamada, Itaru Yasufuku et al.
2026-09-11 · DOI: 10.1007/s12029-026-01591-yPredictors of Hepatic Decompensation Post-Y90 Treatment in Hepatocellular Carcinoma: New Insights into Segmental TARE and Post-Treatment Dosimetry
Ali Afrasiabi, Bahareh Gholami, Andrew M. Moon, Alex Villalobos et al.
2026-09-10 · DOI: 10.1007/s12029-026-01542-7Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Advanced Gastric and Gastroesophageal Junction Cancer: Evidence, Sequencing, Patient Selection, and Clinical Decision-Making
Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa et al.
2026-09-10 · DOI: 10.1007/s12029-026-01590-zGeographic and Ethnic Variation in Early-onset Colorectal Cancer: A Contemporary Scoping Review of Epidemiologic, Molecular, and Survival Patterns
Adhari ALZaabi, Mohammed ALHabsi, Ali ALHabsi, Almaqdad ALAmri et al.
2026-09-09 · DOI: 10.1007/s12029-026-01558-zCorrection: Gastric Cancer Incidence in Iran: Trends and Projections to 2030 Based on Global Burden of Disease 2021 Estimates
Fatemeh Shahbazi, Faezeh Heidari, Ali Khezriyan, Erfan Ayubi et al.
2026-09-08 · DOI: 10.1007/s12029-026-01574-zReviews
Community Reviews
Version History
October 4, 2026 at 9:14 pm
October 2, 2026